Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2001 December;49(6) > Minerva Cardioangiologica 2001 December;49(6):363-8





A Journal on Heart and Vascular Diseases

Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,695




Minerva Cardioangiologica 2001 December;49(6):363-8


language: Italian

Evaluation of resistance to activated protein C in patients suffeting from myocardial infarction

Avellone G., Di Garbo V., Di Raimondo D., Bono M., Abruzzese G., De Simone R., Raneli G.

Full text temporarily not available online. Contact us  

Background. It is known that resistance to activated protein C (APCR), often associated with a single point mutation (Arg506->Gln) in the coagulation factor V gene (factor V Leiden), is the most frequent inherited abnormality of blood coagulation. It plays a key role as pathogenetic factor of venous thromboembolism, but its association with an increased risk of arterial thrombosis is uncertain. Aim of the present study was to evaluate the prevalence of APCR in men, who suffered myocardial infarction more than 6 months earlier and without cardiovascular risk factors (hypercholesterolemia, smoking, diabetes, obesity and hypertension).
Methods. The study was carried on 20 men aged <65 years who have suffered myocardial infarction. Twenty healthy subjetcs matched for sex and age were recruited as controls. We determined: PTT, PTT-PCA (Activated Protein C), PTT-PCA/PTT, AntiThrombin III, Protein C, Protein S, Fibrinogen, Glucose, Triglycerides, Cholesterol, HDL-C, LDL-C, APO A1, APO B100, Lp(a), oxizided LDL antibody and some components of the complement system (C3c, C4).
Results. In the group of patients there were six subjects (30%) with APCR, while there were no subjects in the control group (0%) with APCR. Patients were subdivided into two groups: with and without APCR. Patients with APCR displayed significantly higher levels of fibrinogen (367.5±48.4 vs 268.3±37.7), LDL-C (147.0 ±20.7 vs 125.8±25,6), APO B100 (133.8±29.8 vs 121.8±31.5), oxizide LDL antibody (596.8±357 vs 315.3±179.6) and C4 (45.6±10 vs 37.85±11,3). Significant positive correlations (p<0.05) were observed between PTT-PCA/PTT ratio and fibrinogen (r=0.68) and between PTT-PCA/PTT ratio and oxizided LDL antibody (r=0.61).
Conclusions. In conclusion, the high prevalence of APCR (30%) in our patients seems to be important in order to carry out a primary prevention of arterial thrombosis and a secondary prevention of new thromboembolic complications.

top of page

Publication History

Cite this article as

Corresponding author e-mail